Literature DB >> 21744088

Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.

Luis V Syro1, Jamie L Sundsbak, Bernd W Scheithauer, Rodrigo A Toledo, Mauricio Camargo, Christina M Heyer, Tomoko Sekiya, Humberto Uribe, Jorge I Escobar, Martin Vasquez, Fabio Rotondo, Sergio P A Toledo, Kalman Kovacs, Eva Horvath, Dusica Babovic-Vuksanovic, Peter C Harris.   

Abstract

A 39-year-old woman with autosomal dominant polycystic kidney disease (ADPKD) presented with acromegaly and a pituitary macroadenoma. There was a family history of this renal disorder. She had undergone surgery for pituitary adenoma 6 years prior. Physical examination disclosed bitemporal hemianopsia and elevation of both basal growth hormone (GH) 106 ng/mL (normal 0-5) and insulin-like growth factor (IGF-1) 811 ng/mL (normal 48-255) blood levels. A magnetic resonance imaging scan disclosed a 3.0 cm sellar and suprasellar mass with both optic chiasm compression and left cavernous sinus invasion. Pathologic, cytogenetic, molecular and in silico analysis was undertaken. Histologic, immunohistochemical and ultrastructural studies of the lesion disclosed a sparsely granulated somatotroph adenoma. Standard chromosome analysis on the blood sample showed no abnormality. Sequence analysis of the coding regions of PKD1 and PKD2 employing DNA from both peripheral leukocytes and the tumor revealed the most common PKD1 mutation, 5014_5015delAG. Analysis of the entire SSTR5 gene disclosed the variant c.142C>A (p.L48M, rs4988483) in the heterozygous state in both blood and tumor, while no pathogenic mutations were noted in the MEN1, AIP, p27Kip1 and SSTR2 genes. To our knowledge, this is the fourth reported case of a GH-producing pituitary adenoma associated with ADPKD, but the first subjected to extensive morphological, ultrastructural, cytogenetic and molecular studies. The physical proximity of the PKD1 and SSTR5 genes on chromosome 16 suggests a causal relationship between ADPKD and somatotroph adenoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21744088      PMCID: PMC3905832          DOI: 10.1007/s11102-011-0325-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  34 in total

Review 1.  Molecular biology of somatostatin receptors.

Authors:  T Reisine; G I Bell
Journal:  Endocr Rev       Date:  1995-08       Impact factor: 19.871

2.  Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.

Authors:  E Ballarè; L Persani; A G Lania; M Filopanti; E Giammona; S Corbetta; S Mantovani; M Arosio; P Beck-Peccoz; G Faglia; A Spada
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 3.  New medical treatment for acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

4.  The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome.

Authors:  R Sandford; B Sgotto; T Burn; S Brenner
Journal:  Genomics       Date:  1996-11-15       Impact factor: 5.736

Review 5.  The role of somatostatin receptors in the medical treatment of acromegaly.

Authors:  G Vitale; R Pivonello; D Ferone; M C De Martino; R S Auriemma; M Caraglia; A Abbruzzese; G Lombardi; A Colao
Journal:  Dig Liver Dis       Date:  2004-02       Impact factor: 4.088

6.  [Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease].

Authors:  R Fajfr; B Müller; P Diem
Journal:  Praxis (Bern 1994)       Date:  2002-06-19

Review 7.  Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.

Authors:  Ilan Shimon
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 8.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

9.  Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder.

Authors:  M Nyegaard; A D Børglum; T G Bruun; D A Collier; C Russ; O Mors; H Ewald; T A Kruse
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

10.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  5 in total

1.  Transcriptome Analyses of Female Somatotropes and Lactotropes Reveal Novel Regulators of Cell Identity in the Pituitary.

Authors:  Michael T Peel; Yugong Ho; Stephen A Liebhaber
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

Review 2.  The Genetics of Pituitary Adenomas.

Authors:  Christina Tatsi; Constantine A Stratakis
Journal:  J Clin Med       Date:  2019-12-21       Impact factor: 4.241

3.  A RARE CASE OF ACROMEGALY AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: CASE REPORT AND BRIEF REVIEW OF LITERATURE.

Authors:  Swayamsidha Mangaraj; Debasish Patro; Arun Kumar Choudhury; Anoj Kumar Baliarsinha
Journal:  AACE Clin Case Rep       Date:  2019-06-07

Review 4.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

5.  Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.

Authors:  Ramón Peces; Rocío Mena; Yolanda Martín; Concepción Hernández; Carlos Peces; Dolores Tellería; Emilio Cuesta; Rafael Selgas; Pablo Lapunzina; Julián Nevado
Journal:  Mol Genet Genomic Med       Date:  2020-06-13       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.